Abstract
Renal artery stenting for Atherosclerotic renovascular disease (ARVD) has been a subject of debate for the last two decades. A subset of patients with severe ARVD and large renal mass involvement, who were misrepresented in latest large clinical trials, could gain benefit from this strategy. This is
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have